Compared with other solid malignancies, targeted therapies for gastric cancer are still scarce, which may be mainly attributed to the relative lag in the development of effective and druggable oncoproteins. Currently, most of the applied targets such as HER2, VEGFR, and CLDN18.2 are membrane proteins, which are more favorable for pharmaceutical development. However, few of these targets can produce satisfactory results with only a single use, while the combination of multiple drugs may often increase toxicity. Compared to membrane proteins, intracellular components of signaling pathways and downstream targets have drawn more attention due to their larger target selection pool and better anti-tumor efficacy, such as PI3K-AKT and ERK-MAPK pathways. Moreover, cutting-edge technologies including ADCs and PROTACs have recently been brought out, which facilitate the development of undruggable targets into druggable targets while well controlling toxicity. Therefore, not only should we continue to develop novel oncoproteins, but their pharmaceutical prospects and clinical translation also deserve attention.
This Research Topic aims to investigate more clinically effective oncoproteins for gastric cancer, as well as to use cutting-edge pharmaceutical technologies to make them druggable and tolerable. We hope that all of these basic research findings would be translated into benefits that patients could use to combat carcinogenesis. We welcome submissions covering but are not limited to the following:
1) Molecular regulatory mechanisms of gastric carcinogenesis
2) Potential development of ADCs and PROTACs in targeted therapy of gastric cancer
3) Preclinical and clinical studies on novel therapeutic targets of gastric cancer
4) New preclinical models for gastric cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Compared with other solid malignancies, targeted therapies for gastric cancer are still scarce, which may be mainly attributed to the relative lag in the development of effective and druggable oncoproteins. Currently, most of the applied targets such as HER2, VEGFR, and CLDN18.2 are membrane proteins, which are more favorable for pharmaceutical development. However, few of these targets can produce satisfactory results with only a single use, while the combination of multiple drugs may often increase toxicity. Compared to membrane proteins, intracellular components of signaling pathways and downstream targets have drawn more attention due to their larger target selection pool and better anti-tumor efficacy, such as PI3K-AKT and ERK-MAPK pathways. Moreover, cutting-edge technologies including ADCs and PROTACs have recently been brought out, which facilitate the development of undruggable targets into druggable targets while well controlling toxicity. Therefore, not only should we continue to develop novel oncoproteins, but their pharmaceutical prospects and clinical translation also deserve attention.
This Research Topic aims to investigate more clinically effective oncoproteins for gastric cancer, as well as to use cutting-edge pharmaceutical technologies to make them druggable and tolerable. We hope that all of these basic research findings would be translated into benefits that patients could use to combat carcinogenesis. We welcome submissions covering but are not limited to the following:
1) Molecular regulatory mechanisms of gastric carcinogenesis
2) Potential development of ADCs and PROTACs in targeted therapy of gastric cancer
3) Preclinical and clinical studies on novel therapeutic targets of gastric cancer
4) New preclinical models for gastric cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.